financetom
Business
financetom
/
Business
/
BRIEF-Bitgo Holdings Files Registration Statement For IPO - SEC Filing
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
BRIEF-Bitgo Holdings Files Registration Statement For IPO - SEC Filing
Sep 21, 2025 4:29 AM

Sept 19 (Reuters) -

SEC Filing:

* BITGO HOLDINGS INC - FILES REGISTRATION STATEMENT FOR IPO

- SEC

FILING

* BITGO HOLDINGS: FILES FOR IPO FOR CLASS A COMMON STOCK -

SEC

FILING

* BITGO HOLDINGS INC - APPLIES TO LIST CLASS A COMMON STOCK

ON

NYSE UNDER SYMBOL "BTGO" - SEC FILING

* BITGO HOLDINGS: DO NOT HAVE CURRENT PLANS TO PAY ANY

DIVIDENDS

ON CAPITAL STOCK IN THE FORESEEABLE FUTURE

* BITGO HOLDINGS, INC - WELLS FARGO SECURITIES, CANACCORD

GENUITY,

DEUTSCHE BANK SECURITIES, KEEFE, BRUYETTE & WOODS ARE

UNDERWRITERS TO IPO

* BITGO HOLDINGS INC SAYS GOLDMAN SACHS & CO. LLC,

CITIGROUP,

MIZUHO ARE UNDRWRITERS TO IPO

* BITGO HOLDINGS INC SAYS WEDBUSH SECURITIES ,

ROSENBLATT,

SOFI ARE UNDRWRITERS TO IPO

* BITGO HOLDINGS, INC - CANTOR, CLEAR STREET, COMPASS POINT,

CRAIG-HALLUM ARE UNDERWRITERS TO IPO

* BITGO HOLDINGS: FOR SIX MONTHS ENDED JUNE 30 2025, REVENUE

$4.2

BILLION, NET LOSS $12.6 MILLION - SEC FILING

Source text:

Further company coverage: [ ]

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
What other health conditions are weight-loss drugs being used and tested for?
What other health conditions are weight-loss drugs being used and tested for?
Nov 24, 2025
(Updates to add Novo's Alzheimer trial failure) By Patrick Wingrove Nov 24 (Reuters) - Novo Nordisk said an older version of its weight-loss drug semaglutide failed to meet its main goal in late-stage trials testing whether the medicine can slow cognitive decline in Alzheimer's patients. The results is a blow to hopes that Alzheimer's could open a major new market...
Osisko Development Agrees to Divest San Antonio Project to Axo Copper
Osisko Development Agrees to Divest San Antonio Project to Axo Copper
Nov 24, 2025
08:08 AM EST, 11/24/2025 (MT Newswires) -- Osisko Development's ( ODV ) share price rose 1.3% at last look Monday in New York Stock Exchange pre-market trading as the company agreed to sell the San Antonio gold project in Mexico to Axo Copper ( AXOCF ) . The sale is part of Osisko Development's ( ODV ) strategy to focus...
Fairbanks Morse Defense to Acquire Truflo Marine from IMI
Fairbanks Morse Defense to Acquire Truflo Marine from IMI
Nov 24, 2025
Expanded valve and actuator design and manufacturing capabilities further expand FMD offerings and global customer base BELOIT, Wis.--(BUSINESS WIRE)-- Fairbanks Morse Defense (FMD), a portfolio company of Arcline Investment Management, has entered into an agreement with IMI plc, to acquire its Birmingham, UK-based Truflo Marine business. This strategic acquisition significantly enhances the company’s valve design, engineering, and manufacturing capabilities...
Ocular Therapeutix Begins Phase 3 Registrational Program to Potentially Treat Non-Proliferative Diabetic Retinopathy
Ocular Therapeutix Begins Phase 3 Registrational Program to Potentially Treat Non-Proliferative Diabetic Retinopathy
Nov 24, 2025
08:11 AM EST, 11/24/2025 (MT Newswires) -- Ocular Therapeutix ( OCUL ) said Monday that it has initiated a phase 3 registrational program for the potential treatment of non-proliferative diabetic retinopathy with Axpaxli. Ocular said that the first patient has been randomized in the phase 3 Helios-3 trial, which will include 930 subjects with moderately severe to severe non-proliferative diabetic...
Copyright 2023-2026 - www.financetom.com All Rights Reserved